

## FROM LAB TO MARKET: THE CANADIAN SOLUTION TO ATRIAL FIBRILLATION

Canada's hunger for innovation makes it a great place for Medtronic, Inc to invest. Based in Montréal, Medtronic CryoCath designs, develops and manufactures a new therapy for atrial fibrillation: a rapid, irregular heartbeat that affects seven million people worldwide and is the leading cause of strokes.

*"Pioneered in partnership with the Montréal Heart Institute, the Arctic Front Cardiac CryoAblation Catheter System now brings life-changing therapy to patients around the globe. Montréal is the only location in the world manufacturing this innovative technology. Medtronic CryoCath is one of the company's fastest growing divisions, doubling sales each year since 2009. Medtronic remains committed to Canada and looks forward to the evolution of its medical technology strategies and to becoming a trusted partner in delivering innovative health system solutions."*

Neil Fraser, President  
Medtronic of Canada Ltd.

Also ranking high among the nation's top R&D spenders are several regionally headquartered companies such as **Apotex**, **Biovail** (which recently merged with **Valeant**). Other large R&D-intensive Canadian companies in the sector include **AEterna Zentaris**, **Aptalis Pharma**, **Bioniche Life Science**, **Cardiome Pharma**, **Pharmascience**, **Tekmira Pharmaceuticals Corporation**, and **Theratechnologies**.

### AWARD-WINNING BOEHRINGER INGELHEIM RECOGNIZES UNIVERSITY PARTNERSHIP

Boehringer Ingelheim (Canada) received the *Prix Galien* Canada 2011, Innovative Product Award for its treatment for stroke prevention.

*"The development of PRADAX® represents an important milestone in Canadian pharmaceutical history (...) we are proud to say this global program was coordinated out of McMaster University in Hamilton, Ontario".*

Dr. Theodore Witek, President and CEO  
Boehringer Ingelheim (Canada) Ltd.

### Extensive Public Support

Another example of public support for the industry came in July 2011, when Ontario's Research and Innovation Ministry announced a \$344 million expansion of the **MaRS Discovery District** in downtown Toronto. Located near major teaching hospitals, the District houses international corporations such as **GlaxoSmithKline** and **Merck**, several fast-growth biotech firms as well as public R&D centres such as the **Ontario Brain Institute**, the **Ontario Cancer Biomarker Network** and the **Ontario Genomics Institute**. The expansion, to be completed in 2013, will also house the **Ontario Institute for Cancer Research**, along with **Public Health Ontario's** central lab, which plays a key role in the prevention and control of infectious diseases.